Teva Pharmaceuticals
TEVA
795 hedge funds and large institutions have $26B invested in Teva Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 69 funds opening new positions, 268 increasing their positions, 324 reducing their positions, and 75 closing their positions.
4% less call options, than puts
Call options by funds: $595M | Put options by funds: $620M
8% less first-time investments, than exits
New positions opened: 69 | Existing positions closed: 75
2% less funds holding
Funds holding: 812 → 795 (-17)
2.34% less ownership
Funds ownership: 58.38% → 56.04% (-2.3%)
13% less capital invested
Capital invested by funds: $30B → $26B (-$3.92B)
15% less funds holding in top 10
Funds holding in top 10: 41 → 35 (-6)
17% less repeat investments, than reductions
Existing positions increased: 268 | Existing positions reduced: 324
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$310M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$295M |
| 3 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
+$202M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$188M |
| 5 |
JP Morgan Chase
New York
|
+$179M |
Top Sellers
TEVA Hedge Fund Activity: Q3 2016 in Review
795 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2016, worth a combined $26B — down 13% from $30B a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of TEVA and 69 opened new positions — a net loss of 6 holders — while 324 trimmed existing stakes and 268 added.
The largest buyer was Morgan Stanley, adding an estimated $310M. The largest seller was Viking Global Investors, cutting an estimated $420M.
- 795 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2016, down from 812 in Q2 2016.
- Funds reported $26B of Teva Pharmaceuticals stock for Q3 2016, down 13% quarter-over-quarter.
- 69 funds opened new Teva Pharmaceuticals positions in Q3 2016 and 75 closed out, a net change of -6 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2016 was Morgan Stanley, an estimated $310M added.
- The largest Teva Pharmaceuticals seller in Q3 2016 was Viking Global Investors, an estimated $420M sold.
Based on aggregated 13F filings for Q3 2016.